DEGEVMA approval strengthens Teva biosimilar pipeline as company shifts beyond traditional generics

Teva Pharmaceutical Industries is adding another oncology-facing product to its U.S. biosimilar portfolio after securing FDA approval for DEGEVMA, a biosimilar to Amgen’s Xgeva used to prevent and treat serious bone complications associated with cancer. The approval gives Teva access to the higher-dose side of the denosumab market only months after the FDA cleared PONLIMSI, its biosimilar to Prolia, allowing the company to compete across both major denosumab franchises. Regulatory approval, however, is only the first step because DEGEVMA is entering a crowded U.S. field containing numerous approved Xgeva biosimilars, making pricing, contracting, reimbursement and reliable supply central to commercial uptake. For Teva, the launch is therefore less about creating a new clinical market and more about using its scale to capture share from an established biologic as the company expands biosimilars alongside its higher-growth branded medicines.

The approval fits into a broader transformation underway at Teva. Second-quarter revenue reached $4.14 billion, while its three key innovative brands generated more than $1 billion combined and grew 43% year over year in local-currency terms, even as U.S. generic revenue declined sharply. Biosimilars offer another route to offset pressure within mature generics without requiring Teva to discover an entirely new medicine, but the increasingly crowded denosumab market means DEGEVMA will have to compete aggressively for hospital and payer contracts rather than benefiting from scarcity.

DEGEVMA gives Teva access to Xgeva’s oncology market alongside its Prolia biosimilar

DEGEVMA contains denosumab-adet and has been approved as a biosimilar to Xgeva across the reference product’s U.S. indications. The 120 mg formulation can be used to prevent skeletal-related events in patients with multiple myeloma or bone metastases from solid tumors, while additional indications include certain patients with giant cell tumor of bone and hypercalcemia of malignancy that has not responded adequately to bisphosphonate treatment.

Those indications put DEGEVMA primarily into oncology and specialist treatment settings. Cancer that spreads to bone can cause fractures, spinal cord compression and other complications requiring radiation or surgery, creating a significant need for therapies that suppress excessive bone breakdown.

Denosumab works by inhibiting receptor activator of nuclear factor kappa B ligand, or RANKL, preventing it from activating the RANK pathway responsible for osteoclast formation and activity. Suppressing osteoclasts slows bone resorption and can reduce the frequency of skeletal complications in patients with cancers involving bone.

Teva already received FDA approval for PONLIMSI earlier this year. That 60 mg denosumab-adet product references Prolia and covers osteoporosis and other conditions associated with elevated fracture risk, while DEGEVMA uses the 120 mg formulation corresponding to Xgeva’s oncology-related indications.

Together, the products give Teva a paired denosumab strategy covering two clinically distinct markets built around the same underlying biological target. That could provide commercial advantages when negotiating with larger health systems or payers that purchase biologics across multiple specialties, although Teva has not disclosed the pricing or contracting strategy it intends to use for the U.S. launches.

Teva enters a denosumab biosimilar market that already has several competing products

DEGEVMA arrives well after the competitive race around denosumab began. The FDA has already approved numerous products referencing Prolia and Xgeva, including Wyost, Xbryk, Osenvelt, Conexxence, Xtrenbo and several additional denosumab biosimilars introduced across 2025 and 2026.

That density changes the commercial significance of Teva’s approval. Biosimilar markets often reward early entrants because they can secure payer contracts and establish physician familiarity before additional competitors arrive, but later entrants may need stronger pricing concessions or broader commercial packages to displace products already gaining formulary access.

Wyost also carries an interchangeable designation with Xgeva, an additional FDA regulatory status that DEGEVMA’s approval announcement does not claim. Interchangeability does not mean Wyost is clinically superior to another FDA-approved biosimilar, but it can provide additional substitution flexibility under applicable laws and purchasing systems.

For physician-administered oncology drugs, however, purchasing contracts may ultimately have greater practical influence than pharmacy substitution. Hospitals and cancer centers frequently negotiate acquisition prices directly or through group purchasing organizations, meaning discounts, rebates, reimbursement economics and dependable inventory can significantly affect which biosimilar gains share.

Teva has substantial experience in complex generics and injectable medicines, which could help with distribution and contracting. The company also already markets biosimilars including Truxima and Simlandi, giving it an existing U.S. commercial infrastructure rather than requiring DEGEVMA to build one from scratch.

Biosimilars could help offset pressure inside Teva’s large but declining U.S. generic business

The DEGEVMA approval comes as Teva’s revenue mix is changing rapidly. U.S. generic products, including biosimilars, generated $660 million during the second quarter, down 31% from $961 million a year earlier, largely because of falling revenue from generic lenalidomide as competition increased.

Higher sales from Teva’s existing biosimilars partially offset that decline, showing why the company continues adding complex biologics despite intense competition. Unlike conventional generic tablets, biosimilars are substantially more difficult and expensive to develop and manufacture, creating higher barriers to entry and potentially more durable economics for successful products.

Even so, biosimilars are not currently the main growth engine behind Teva’s improving business profile. AUSTEDO generated $696 million globally in the second quarter and grew 40% in local currency, AJOVY reached $244 million with 56% growth, and UZEDY generated $77 million while increasing 43%. Combined revenue from the three key innovative brands exceeded $1 billion for the quarter.

That distinction matters for investors assessing DEGEVMA. One biosimilar approval is unlikely to materially alter Teva’s near-term financial outlook, particularly when several competing denosumab products are already available. Its importance is cumulative: each new biosimilar broadens Teva’s portfolio and provides additional revenue opportunities that can help stabilize the generics business while innovative medicines deliver higher growth.

Teva has additional biosimilar programs targeting established biologics across several therapeutic categories. A sufficiently broad portfolio can improve sales-force efficiency and contracting leverage because hospitals and payers may negotiate across multiple products rather than evaluate each medicine entirely in isolation.

Teva’s broader Pivot to Growth strategy is increasingly centered on branded medicines and complex products

Teva’s second-quarter performance shows the company moving away from reliance on conventional generics as its main source of growth. Total revenue declined 1% year over year in U.S. dollar terms to $4.14 billion, but gross margin improved to 52.0% from 50.3% as higher AUSTEDO revenue partly offset weaker generic sales.

Management has framed that shift under its Pivot to Growth strategy, emphasizing innovative medicines, complex products and pipeline assets while maintaining Teva’s global generics infrastructure. DEGEVMA fits the complex-product portion of that strategy because biosimilar development requires advanced analytical, manufacturing and regulatory capabilities beyond those used for straightforward oral generics.

The company’s existing scale may be particularly valuable in a market such as denosumab where individual competitors are unlikely to differentiate meaningfully on efficacy. The FDA biosimilar pathway requires highly similar biological performance and no clinically meaningful differences from the reference product, leaving commercial factors to play a larger role after approval.

That also limits the clinical marketing story surrounding DEGEVMA. Teva cannot credibly position the product as more effective than Xgeva or other biosimilars based simply on FDA approval, so success will depend on access, affordability, supply reliability and confidence among physicians and health systems.

For healthcare systems, additional competition could still be beneficial. More suppliers create greater potential for price competition and reduce reliance on a single manufacturer, although actual savings will depend on negotiated discounts and how quickly payers encourage biosimilar utilization.

Teva shares remain near a 52-week high as investors focus on the wider turnaround

The market response to DEGEVMA should be viewed in the context of Teva’s broader recovery rather than as a direct verdict on one biosimilar. Teva’s New York-listed shares closed the previous trading session at $39.19 after declining 2.6%, but the stock recently reached a 52-week high of $40.79 and has traded substantially above its 52-week low of roughly $18.

Earlier in the September 28 session, shares were trading around $38.85, down less than 1%, leaving the company with a market capitalization of approximately $45 billion. The stock’s position near its yearly high suggests investor attention is centered primarily on Teva’s expanding innovative portfolio, improving margins and broader turnaround rather than incremental regulatory milestones within biosimilars.

Analyst expectations also remain constructive. Data compiled by StockAnalysis show an average Buy rating among six analysts and an average 12-month price target of $44, although analyst forecasts are opinions and should not be treated as predictions of future share performance.

DEGEVMA nevertheless adds another piece to the commercial portfolio underlying that turnaround. Teva now has FDA-approved denosumab biosimilars addressing both the Prolia and Xgeva markets and an established infrastructure capable of selling complex biologics alongside generic and branded medicines.

The decisive question will now move from regulatory approval to execution. In a market containing multiple Xgeva biosimilars, DEGEVMA’s value to Teva will depend on how much share the company can win, what pricing it must offer to secure that share and whether the paired DEGEVMA-PONLIMSI portfolio creates enough contracting leverage to distinguish Teva from competing manufacturers.

Key takeaways from Teva’s DEGEVMA approval and expanding U.S. biosimilar strategy

• FDA approval gives Teva a DEGEVMA biosimilar covering all approved Xgeva indications, including cancer-related skeletal complications.
• DEGEVMA complements PONLIMSI, giving Teva denosumab biosimilars spanning both the Xgeva and Prolia markets.
• Teva is entering an already crowded field containing several FDA-approved denosumab biosimilars.
• Commercial success is likely to depend heavily on pricing, payer contracts, hospital access and supply reliability.
• Teva’s existing U.S. biosimilar infrastructure could support DEGEVMA without requiring an entirely new commercial network.
• U.S. generic and biosimilar revenue fell 31% in the second quarter, increasing the importance of newer complex products.
• Teva’s three key innovative brands grew 43% and generated more than $1 billion during the quarter.
• DEGEVMA is unlikely to transform Teva’s finances alone but adds another revenue opportunity to its expanding biosimilar portfolio.
• Teva shares remain near their 52-week high as investors focus on the company’s broader Pivot to Growth strategy.